ROYAL BANK OF CANADA - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 4 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
ROYAL BANK OF CANADA ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$19,000
-5.0%
16,602
+16.6%
0.00%
Q2 2023$20,000
+900.0%
14,234
+1110.4%
0.00%
Q1 2023$2,0001,176
+253.2%
0.00%
Q4 2022$0
-100.0%
333
-89.1%
0.00%
Q3 2022$3,000
-62.5%
3,054
-41.3%
0.00%
Q2 2022$8,000
-38.5%
5,204
-38.6%
0.00%
Q1 2022$13,000
-81.7%
8,476
-70.7%
0.00%
Q4 2021$71,000
+73.2%
28,963
+77.8%
0.00%
Q3 2021$41,000
+57.7%
16,293
+79.3%
0.00%
Q2 2021$26,000
+136.4%
9,088
+97.0%
0.00%
Q1 2021$11,000
-15.4%
4,613
-41.2%
0.00%
Q4 2020$13,000
+62.5%
7,842
-2.4%
0.00%
Q3 2020$8,000
-20.0%
8,037
-29.1%
0.00%
Q2 2020$10,000
+233.3%
11,338
+268.6%
0.00%
Q1 2020$3,000
-66.7%
3,076
-68.4%
0.00%
Q4 2019$9,000
+12.5%
9,743
+21.8%
0.00%
Q3 2019$8,0007,9980.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2023
NameSharesValueWeighting ↓
Defender Capital, LLC. 5,036,720$14,354,0004.77%
BROADWOOD CAPITAL INC 34,005,379$96,915,0004.33%
Prescott General Partners LLC 1,851,851$5,278,0000.17%
Raffles Associates 43,590$124,0000.10%
Laidlaw Wealth Management LLC 123,730$353,0000.09%
DCF Advisers, LLC 74,500$212,0000.08%
Beirne Wealth Consulting Services, LLC 45,000$128,0000.07%
Strategic Wealth Investment Group, LLC 64,232$183,0000.06%
Paradigm, Strategies in Wealth Management, LLC 19,775$56,0000.05%
Fort Sheridan Advisors LLC 47,931$137,0000.05%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders